Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, et al. Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105–22.
Vega Cano KS, Marmolejo Castañeda DH, Escrivá-de-Romaní S, Saura C. Systemic therapy for HER2-positive metastatic breast cancer: current and future trends. Cancers. 2022;15(1):51.
Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast (Edinburgh Scotland). 2022;66:15–23.
Nader-Marta G, Martins-Branco D, de Azambuja E. How we treat patients with metastatic HER2-positive breast cancer. ESMO open. 2022;7(1):100343.
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, et al. Pertuzumab retreatment for HER2-positive advanced breast cancer: a randomized, open-label phase III study (PRECIOUS). Cancer Sci. 2022;113(9):3169–79.
Rizzo A, Cusmai A, Acquafredda S, Giovannelli F, Rinaldi L, Misino A, Palmiotti G. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncol (London England). 2022;18(18):2301–9.
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.
Rassy E, Rached L, Pistilli B. Antibody drug conjugates targeting HER2: clinical development in metastatic breast cancer. Breast (Edinburgh Scotland). 2022;66:217–26.
Ferrando-Díez A, Felip E, Pous A, Bergamino Sirven M, Margelí M. Targeted therapeutic options and future perspectives for HER2-Positive Breast Cancer. Cancers. 2022;14(14):3305.
Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated erbb2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573–84.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74.
Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, et al. Trastuzumab deruxtecan in HER2-positive Breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840–7.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in Independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418–23.
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early Breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet (London England). 2017;389(10075):1195–205.
Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, et al. Mutation tracking in circulating Tumor DNA predicts relapse in early Breast cancer. Sci Transl Med. 2015;7(302):302ra133.
Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485–505.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.
Barbieri MA, Sorbara EE, Cicala G, Santoro V, Cutroneo PM, Franchina T, Spina E. Adverse drug reactions with HER2-positive breast cancer treatment: an analysis from the italian pharmacovigilance database. Drugs – real World Outcomes. 2022;9(1):91–107.
Ma P, Tian H, Shi Q, Liu R, Zhang Y, Qi X, Chen Y. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database. Exp Opin Drug Saf. 2023;22(8):685–96.
Waliany S, Caswell-Jin J, Riaz F, Myall N, Zhu H, Witteles RM, Neal JW. Pharmacovigilance analysis of heart failure associated with Anti-HER2 monotherapies and combination regimens for cancer. JACC CardioOncology. 2023;5(1):85–98.
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.
Deng W, Liu J, Pan H, Li L, Zhou C, Wang X, Shu R, Dong B, Cao D, Li Q, et al. A bispecific antibody based on pertuzumab fab has potent antitumor activity. J Immunotherapy (Hagerstown Md: 1997). 2018;41(1):1–8.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.
Xu B, Li W, Zhang Q, Li Q, Wang X, Li H, Sun T, Yin Y, Zheng H, Feng J, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat. 2023;197(3):503–13.
Xie XF, Zhang QY, Huang JY, Chen LP, Lan XF, Bai X, Song L, Xiong SL, Guo SJ, Du CW. Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic Breast cancer: a single-arm exploratory phase II trial. Breast Cancer Res Treat. 2023;197(1):93–101.
Lavasani SM, Somlo G, Yost SE, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Kruper L, et al. Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary Breast cancer. Cancer. 2023;129(5):740–9.
Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, et al. Combination of Trastuzumab, Pertuzumab, and Docetaxel in patients with Advanced Non-small-cell Lung Cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2022;40(7):719–28.
Ahn HK, Sim SH, Suh KJ, Kim MH, Jeong JH, Kim JY, Lee DW, Ahn JH, Chae H, Lee KH, et al. Response rate and safety of a neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for patients with ERBB2-Positive stage II/III Breast Cancer: the Neo-PATH phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2022;8(9):1271–7.
Kuemmel S, Tondini CA, Abraham J, Nowecki Z, Itrych B, Hitre E, Karaszewska B, Juárez-Ramiro A, Morales-Vásquez F, Pérez-García JM, et al. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic Breast cancer: final analysis of MetaPHER, a phase IIIb single-arm safety study. Breast Cancer Res Treat. 2021;187(2):467–76.
Dai WF, Beca JM, Nagamuthu C, Liu N, de Oliveira C, Earle CC, Trudeau M, Mercer RE, Chan KKW. Comparative effectiveness and safety of pertuzumab and trastuzumab plus chemotherapy vs trastuzumab plus chemotherapy for treatment of metastatic breast cancer. JAMA Netw open. 2022;5(2):e2145460.
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic Breast cancer (PERUSE). Anna Oncol. 2019;30(5):766–73.
Xu B, Li W, Zhang Q, Shao Z, Li Q, Wang X, Li H, Sun T, Yin Y, Zheng H, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic Breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat. 2020;182(3):689–97.
de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, et al. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive Breast cancer in the APHINITY trial. ESMO open. 2023;8(1):100772.
Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized Breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;29(3):646–53.
FDA adverse event reporting system (FAERS). Available at: https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.
Peng J, Wang H, Liu Z, Xu ZL, Wang MX, Chen QM, Wu ML, Ren XL, Liang QH, Liu FP, et al. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database. Front Pharmacol. 2022;13:1017391.
Chen J, Wen Y, Chu X, Liu Y, Su C. Pulmonary adverse events associated with Hypertension in non-small cell Lung cancer patients receiving PD-1/PD-L1 inhibitors. Front Pharmacol. 2022;13:944342.
Jiang JJ, Zhao B, Li J. Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system. J Clin Pharm Ther. 2022;47(10):1556–62.
Zhang M, Li H, Huang L, Liu Y, Jiao XF, Zeng L, Jia ZJ, Cheng G, Zhang L, Zhang W. Drug-associated kidney injury in children: a disproportionality analysis of the FDA adverse event reporting system. Eur J Pediatrics. 2023;182(10):4655–61.
Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179.
Guo M, Shu Y, Chen G, Li J, Li F. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci Rep. 2022;12(1):20601.
Hauben M. A brief primer on automated signal detection. Ann Pharmacother. 2003;37(7–8):1117–23.
Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Exp Opin Drug Saf. 2005;4(5):929–48.
Norén GN, Bate A, Orre R, Edwards IR. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med. 2006;25(21):3740–57.
Sundström A, Hallberg P. Data mining in pharmacovigilance–detecting the unexpected: the role of index of suspicion of the reporter. Drug Saf. 2009;32(5):419–27.
Szarfman A, Machado SG, O’Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of Drugs and events in the US FDA’s spontaneous reports database. Drug Saf. 2002;25(6):381–92.
Wang S, Guo M, Zhang X, Fan P, Jin Z. PARP inhibitor-related haemorrhages: what does the real-world study say? Front Oncol. 2023;13:1070343.
Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG. An overview of the Safety and Efficacy of Monoclonal antibodies for the Chronic Obstructive Pulmonary Disease. Biologics. 2021;15:363–74.
Li Sun SS, Wang T, Li J. aJL: parallel ADR detection based on spark and BCPNN. Tsinghua Sci Technol. 2019;24(2):195–206.
Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D’Andre S, Ahn ER, O’Lone R, Halabi S, Grantham GN, et al. Pertuzumab Plus Trastuzumab in patients with Colorectal Cancer with ERBB2 amplification or ERBB2/3 mutations: results from the TAPUR Study. JCO Precis Oncol. 2022;6:e2200306.
Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22(9):1290–300.
Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S, Leone F, Bergamo F, Zagonel V, Ciardiello F, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic Colorectal cancer: the phase II HERACLES-B trial. ESMO open. 2020;5(5): e000911.
Alhussein MM, Mokbel A, Cosman T, Aghel N, Yang EH, Mukherjee SD, Dent S, Ellis PM, Dhesy-Thind S, Leong DP. Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis. CJC open. 2021;3(11):1372–82.
Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain metastases in HER2-positive breast cancer: current and novel treatment strategies. Cancers. 2021;13(12):2927.
Banys-Paluchowski M, Krawczyk N, Stickeler E, Muller V, Fehm T. New treatment strategies for human epidermal growth factor receptor 2-positive Breast cancer in 2023. Curr Opin Obstet Gynecol. 2023;35(1):54–61.
Zhang J, Li J, Zhu C, Song Y, Xia F, Ma X. Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic Breast cancer: a pooled analysis. Drug Des Devel Ther. 2017;11:3235–44.
Gao J, Swain SM. Pertuzumab for the treatment of breast cancer: a safety review. Exp Opin Drug Saf. 2016;15(6):853–63.
Dang C, Iyengar N, Datko F, D’Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic Breast cancer. J Clin Oncol. 2015;33(5):442–7.
Robert NJ, Goertz HP, Chopra P, Jiao X, Yoo B, Patt D, Antao V. HER2-Positive metastatic Breast Cancer patients receiving Pertuzumab in a community oncology practice setting: treatment patterns and outcomes. Drugs – real World Outcomes. 2017;4(1):1–7.
Li X, Yao L, Wang M, Wang M, Li X, Yu X, Guo J, Dong H, Sun X, Xu Y. Updated bayesian network Meta-analysis of adjuvant targeted treatment regimens for early human epidermal growth factor Receptor-2 positive Breast Cancer. J Breast Cancer. 2020;23(4):410–29.
Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, Galldiks N, de Azambuja E, Berghoff AS, Metellus P, et al. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain Metastasis from solid tumours. Ann Oncol. 2021;32(11):1332–47.
Kumthekar PU, Avram MJ, Lassman AB, Lin NU, Lee E, Grimm SA, Schwartz M, Bell Burdett KL, Lukas RV, Dixit K, et al. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neurooncology. 2023;25(3):557–65.
Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, et al. Tucatinib vs Placebo, both in Combination with Trastuzumab and Capecitabine, for previously treated ERBB2 (HER2)-Positive metastatic Breast Cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncol. 2023;9(2):197–205.
Cavalieri S, Nuzzolese I, Ottini A, Bergamini C, Resteghini C, Colombo E, Alfieri S, Quattrone P, Calareso G, Iacovelli NA, et al. HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients. Front Oncol. 2022;12:1096068.
Tezuka T, Okuzumi S, Nakashima C, Ide T, Imai S, Mitsuboshi S, Kuwahara Y, Takizawa T, Seki M, Minematsu N, et al. Dysautonomia associated with immune checkpoint inhibitors. J Neurol. 2023;270(7):3413–23.
Shi X, Cheng Q, Zhao YZ, Zou SP, Sun MH. A real-world pharmacovigilance study of abaloparatide based on the FDA adverse event reporting System (FAERS). Osteoporos Int. 2023. https://doi.org/10.1007/s00198-023-06877-6.
Add Comment